Regulation, function, and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 8, 2006, Pages 3171-3180

  Matias, Isabel ^a   Gonthier, Marie Paule ^d   Orlando, Pierangelo ^a,b   Martiadis, Vassilis ^e   De Petrocellis, Luciano ^a,c   Cervino, Cristina ^f   Petrosino, Stefania ^a   Hoareau, Laurence ^d   Festy, Franck ^d   Pasquali, Renato ^f   Roche, Regis ^d   Maj, Mario ^e   Pagotto, Uberto ^f   Monteleone, Palmiero ^e   Di Marzo, Vincenzo ^a,c  

^a Institute of Biomolecular Chemistry   (Italy)

^b Biochemistry of Proteins   (Italy)

^c CNR   (Italy)

^d UNIVERSITÉ DE LA RÉUNION   (France)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CALCIUM; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; GLUCOSE; INSULIN; LEPTIN; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ADIPOCYTE; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY MASS; CELL CULTURE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 33747644061     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-2679     Document Type: Article

References (37)

1. Di Marzo V, Bifulco M, De Petrocellis L 2004 The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3:771-784
2. Di Marzo V, Matias I 2005 Endocannabinoid control of food intake and energy balance. Nat Neurosci 8:585-589
3. Vickers SP, Kennett GA 2005 Cannabinoids and the regulation of ingestive behaviour. Curr Drug Targets 6:215-223
4. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL 1998 Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63:PL113-PL117.
5. Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA 2003 Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) 167:103-111
6. Chambers AP, Sharkey KA, Koopmans HS 2004 Cannabinoid (CB)1 receptor antagonist, AM 251, causes a sustained reduction of daily food intake in the rat. Physiol Behav 82:863-869
7. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G 2001 Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410:822-825
8. Kirkham TC, Williams CM, Fezza F, Di Marzo V 2002 Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 136:550-557
9. Williams CM, Kirkham TC 1999 Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 143:315-317
10. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrie PC 2003 Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regu Integr Comp Physiol 284:R345-R353
11. Poirier B, Bidouard JP, Cadrouvele C, Marniquet X, Staels B, O'Connor SE, Janiak P, Herbert JM 2005 The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 7:65-72
12. Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P 2004 CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 28:640-648
13. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thone-Reineke C, Ortmann S, Tomassoni F, Cervino C, Nisoli E, Linthorst AC, Pasquali R, Lutz B, Stalla GK, Pagotto U 2003 The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112:423-431
14. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Offertaler L, Wang L, Kunos G 2005 Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115:1298-1305
15. National Cholesterol Education Program 2001 Detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Bethesda, MD: National Institutes of Health
16. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, RIO-Europe Study Group 2005 Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389-1397
17. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrie P 2003 The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63:908-914
18. Staiger H, Haring HU 2005 Adipocytokines: fat-derived humoral mediators of metabolic homeostasis. Exp Clin Endocrinol Diabetes 113:67-79
19. 2+ signals and insulin secretion in pancreatic β-cell. Cell Calcium 39:155-162
20. Ramirez ZJL, Castro MF, Kuri HW 1992 Quantitation of adipose conversion and triglycerides by staining intra-cyctoplasmic lipids with Oil Red O. Histochemistry 97:493-497
21. Nakhoda A, Wong HA 1979 The induction of diabetes in rats by intramuscular administration of streptozotocin. Experientia 35:1679-1680
22. De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V 2003 Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis 2:1-9
23. Maccarrone M, Bari M, Di Rienzo M, Finazzi-Agro A, Rossi A 2003 Progesterone activates fatty acid amide hydrolase (FAAH) promoter in human T lymphocytes through the transcription factor Ikaros. Evidence for a synergistic effect of leptin. J Biol Chem 278:32726-32732
24. Maccarrone M, Fride E, Bisogno T, Bari M, Cascio MG, Battista N, Finazzi Agro A, Suris R, Mechoulam R, Di Marzo V 2005 Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility. Mol Hum Reprod 11:21-28
25. Hohmeier HE, Newgard CB 2004 Cell lines derived from pancreatic islets. Mol Cell Endocrinol 228:121-128
26. Cote M, Mauriege P, Bergeron J, Almeras N, Tremblay A, Lemieux I, Despres JP 2005 Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab 90:1434-1439
27. Després JP, Golay A, Sjostrom L, the RIO-Lipids Study Group, One-year treatment with rimonabant increases plasma adiponectin levels beyond weight loss: the RIO-Lipids trial. 65th Scientific Sessions of the American Diabetes Association, San Diego, CA, 2005 (Abstract 7-LB)
28. Rosenstok J, The potential of rimonabant in prediabetes: pooled 1-year results from RIO-Lipids, RIO-Europe and RIO-North America studies. 65th Scientific Sessions of the American Diabetes Association, San Diego, CA, 2005, (Abstract 13-LB)
29. Després JP, Golay A, Sjostrom L; Rimonabant in Obesity-Lipids Study Group 2005 Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121-2134
30. Gary-Bobo M, Elachouri G, Scatton B, Le Fur G, Oury-Donat F, Bensaid M 2006 The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 69:471-478
31. Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A, Penarier G, Soubrie P, Le Fur G, Galiegue S, Casellas P 2005 The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 19:1567-1569
32. Valenti M, Vigano D, Cascio MG, Rubino T, Steardo L, Parolaro D, Di Marzo V 2004 Differential diurnal variations of anandamide and 2-arachidonoylglycerol levels in rat brain. Cell Mol Life Sci 61:945-950
33. Berrendero F, Sepe N, Ramos JA, Di Marzo V, Fernandez-Ruiz JJ 1999 Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. Synapse 33:181-191
34. Maccarrone M, Di Rienzo M, Battista N, Gasperi V, Guerrieri P, Rossi A, Finazzi-Agro A 2003 The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. J Biol Chem 278:33896-33903
35. Sipe JC, Waalen J, Gerber A, Beutler E 2005 Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes Relat Metab Disord 29:755-759
36. Monteleone P, Matias I, Martiadis V, De Petrocellis L, Maj M, Di Marzo V 2005 Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 30:1216-1221
37. Engeli S, Janke J, Gorzelniak K, Bohnke J, Ghose N, Lindschau C, Luft FC, Sharma AM 2005 Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54:2838-2843